Browse CR2

Summary
SymbolCR2
Namecomplement component (3d/Epstein Barr virus) receptor 2
Aliases CD21; C3DR; CVID7; SLEB9; EBV receptor; complement C3d receptor; CD antigen CD21; Epstein-Barr virus recepto ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Single-pass type I membrane protein.
Domain PF00084 Sushi repeat (SCR repeat)
Function

Receptor for complement C3Dd, for the Epstein-Barr virus on human B-cells and T-cells and for HNRNPU (PubMed:7753047). Participates in B lymphocytes activation (PubMed:7753047). ; FUNCTION: (Microbial infection) Acts as a receptor for Epstein-Barr virus.

> Gene Ontology
 
Biological Process GO:0002250 adaptive immune response
GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002430 complement receptor mediated signaling pathway
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002455 humoral immune response mediated by circulating immunoglobulin
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002521 leukocyte differentiation
GO:0002757 immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0006956 complement activation
GO:0006958 complement activation, classical pathway
GO:0006959 humoral immune response
GO:0016064 immunoglobulin mediated immune response
GO:0019058 viral life cycle
GO:0019724 B cell mediated immunity
GO:0030098 lymphocyte differentiation
GO:0030183 B cell differentiation
GO:0030260 entry into host cell
GO:0032943 mononuclear cell proliferation
GO:0042100 B cell proliferation
GO:0042113 B cell activation
GO:0044409 entry into host
GO:0046651 lymphocyte proliferation
GO:0046718 viral entry into host cell
GO:0051701 interaction with host
GO:0051806 entry into cell of other organism involved in symbiotic interaction
GO:0051828 entry into other organism involved in symbiotic interaction
GO:0070661 leukocyte proliferation
GO:0072376 protein activation cascade
Molecular Function GO:0001618 virus receptor activity
GO:0001848 complement binding
GO:0004875 complement receptor activity
Cellular Component GO:0043235 receptor complex
> KEGG and Reactome Pathway
 
KEGG hsa04610 Complement and coagulation cascades
hsa04640 Hematopoietic cell lineage
hsa04662 B cell receptor signaling pathway
Reactome -
Summary
SymbolCR2
Namecomplement component (3d/Epstein Barr virus) receptor 2
Aliases CD21; C3DR; CVID7; SLEB9; EBV receptor; complement C3d receptor; CD antigen CD21; Epstein-Barr virus recepto ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CR2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCR2
Namecomplement component (3d/Epstein Barr virus) receptor 2
Aliases CD21; C3DR; CVID7; SLEB9; EBV receptor; complement C3d receptor; CD antigen CD21; Epstein-Barr virus recepto ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CR2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.51 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolCR2
Namecomplement component (3d/Epstein Barr virus) receptor 2
Aliases CD21; C3DR; CVID7; SLEB9; EBV receptor; complement C3d receptor; CD antigen CD21; Epstein-Barr virus recepto ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.410.519
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.4130.175
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3350.698
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1630.802
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.7680.543
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5980.679
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.9460.0752
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15112.1930.15
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11122.0330.227
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.9860.12
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.3070.687
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0710.858
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.46.80.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.48.5-1.11
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382713.23.79.50.388
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221322.77.7150.377
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCR2
Namecomplement component (3d/Epstein Barr virus) receptor 2
Aliases CD21; C3DR; CVID7; SLEB9; EBV receptor; complement C3d receptor; CD antigen CD21; Epstein-Barr virus recepto ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CR2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCR2
Namecomplement component (3d/Epstein Barr virus) receptor 2
Aliases CD21; C3DR; CVID7; SLEB9; EBV receptor; complement C3d receptor; CD antigen CD21; Epstein-Barr virus recepto ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CR2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CR2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCR2
Namecomplement component (3d/Epstein Barr virus) receptor 2
Aliases CD21; C3DR; CVID7; SLEB9; EBV receptor; complement C3d receptor; CD antigen CD21; Epstein-Barr virus recepto ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CR2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCR2
Namecomplement component (3d/Epstein Barr virus) receptor 2
Aliases CD21; C3DR; CVID7; SLEB9; EBV receptor; complement C3d receptor; CD antigen CD21; Epstein-Barr virus recepto ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CR2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCR2
Namecomplement component (3d/Epstein Barr virus) receptor 2
Aliases CD21; C3DR; CVID7; SLEB9; EBV receptor; complement C3d receptor; CD antigen CD21; Epstein-Barr virus recepto ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CR2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCR2
Namecomplement component (3d/Epstein Barr virus) receptor 2
Aliases CD21; C3DR; CVID7; SLEB9; EBV receptor; complement C3d receptor; CD antigen CD21; Epstein-Barr virus recepto ......
Chromosomal Location1q32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CR2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.